Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C5H12N2O2.ClH |
| Molecular Weight | 168.622 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NCCC[C@H](N)C(O)=O
InChI
InChIKey=GGTYBZJRPHEQDG-WCCKRBBISA-N
InChI=1S/C5H12N2O2.ClH/c6-3-1-2-4(7)5(8)9;/h4H,1-3,6-7H2,(H,8,9);1H/t4-;/m0./s1
DescriptionCurator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00129
Curator's Comment: description was created based on several sources, including
https://www.drugbank.ca/drugs/DB00129
Ornithine is an amino acid produced in the urea cycle by the splitting off of urea from arginine. It is a central part of the urea cycle, which allows for the disposal of excess nitrogen. Ornithine is also a precursor of citrulline and arginine. Arginine stimulates the pituitary release of growth hormone. Burns or other injuries affect the state of arginine in tissues throughout the body. As de novo synthesis of arginine during these conditions is usually not sufficient for normal immune function, nor for normal protein synthesis, ornithine may have immunomodulatory and wound-healing activities under these conditions (by virtue of its metabolism to arginine).
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q5T6X5 Gene ID: 222545.0 Gene Symbol: GPRC6A Target Organism: Homo sapiens (Human) |
112.0 µM [EC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | L-Ornithine Approved UseUsed for nutritional supplementation, also for treating dietary shortage or imbalance. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The genome of Mycobacterium leprae: a minimal mycobacterial gene set. | 2001 |
|
| Possible implications of arginase and diamine oxidase in prostatic carcinoma. | 2001 |
|
| Ophthalmologic heterogeneity in subjects with gyrate atrophy of choroid and retina harboring the L402P mutation of ornithine aminotransferase. | 2001 Apr |
|
| Effects of dietary L-arginine on structure and function of flow-restricted vein grafts. | 2001 Apr |
|
| Ornithine transcarbamylase deficiency unmasked because of gastrointestinal bleeding. | 2001 Apr |
|
| Analysis of amino acids in human serum by isocratic reversed-phase high-performance liquid chromatography with electrochemical detection. | 2001 Apr 13 |
|
| Derivatization and chromatographic behavior of the o-phthaldialdehyde amino acid derivatives obtained with various SH-group-containing additives. | 2001 Apr 13 |
|
| CCAAT/enhancer-binding protein beta is required for activation of genes for ornithine cycle enzymes by glucocorticoids and glucagon in primary-cultured hepatocytes. | 2001 Apr 6 |
|
| Is hyperprolinemia type I actually a benign trait? Report of a case with severe neurologic involvement and vigabatrin intolerance. | 2001 Aug |
|
| The potential mechanism for glutamine-induced collagen biosynthesis in cultured human skin fibroblasts. | 2001 Aug |
|
| Classical and slow-binding inhibitors of human type II arginase. | 2001 Aug 7 |
|
| Synthesis and biological activity of novel macrocyclic antifungals: acylated conjugates of the ornithine moiety of the lipopeptidolactone FR901469. | 2001 Feb 26 |
|
| Kinetic mechanism of antiports catalyzed by reconstituted ornithine/citrulline carrier from rat liver mitochondria. | 2001 Jan 19 |
|
| Determination of amino acids by ion-exchange chromatography on filter paper spotted blood samples stored at different temperatures and for different periods: comparison with capillary and venous blood. | 2001 Jul |
|
| Medical and surgical therapy of the cystine stone patient. | 2001 Jul |
|
| Ornithine aminotransferase messenger RNA expression and enzymatic activity in fetal porcine intestine. | 2001 Jul |
|
| Analysis of differentially expressed genes in human hepatocellular carcinoma using suppression subtractive hybridization. | 2001 Jul 20 |
|
| Experimental chronic arthritis and granulomatous inflammation induced by bifidobacterium cell walls. | 2001 Jul-Aug |
|
| Metabolic effects of arginine addition to the enteral feeding of critically ill patients. | 2001 Jul-Aug |
|
| The remarkable hydrophobic effect of a fatty acid side chain on the microbial growth promoting activity of a synthetic siderophore. | 2001 Jun |
|
| Involvement of a transformylase enzyme in siderophore synthesis in Pseudomonas aeruginosa. | 2001 Jun |
|
| Evidence for a spontaneous nitric oxide release from the rat median eminence: influence on gonadotropin-releasing hormone release. | 2001 Jun |
|
| Formation pathways for lysine-arginine cross-links derived from hexoses and pentoses by Maillard processes: unraveling the structure of a pentosidine precursor. | 2001 Jun 29 |
|
| Tryptic hydrolysis of hGH-RH(1-29)-NH2 analogues containing Lys or Orn in positions 12 and 21. | 2001 Mar |
|
| Rat colon ornithine and arginine metabolism: coordinated effects after proliferative stimuli. | 2001 Mar |
|
| Significance of arginase and ornithine in malignant tumors of the human skin. | 2001 May |
|
| Expression, purification, and characterization of human type II arginase. | 2001 May 1 |
|
| Biogenic amines in wines: role of lactic acid bacteria. | 2001 May 15 |
|
| A new receptor molecule for lysine and histidine in water: strong binding of basic amino acid esters by a macrocyclic host. | 2001 May 31 |
|
| Localization of amino acid neurotransmitters following in vitro ischemia and anoxia in the rat retina. | 2001 May-Jun |
|
| Polyamine synthesis and interconversion by the Microsporidian Encephalitozoon cuniculi. | 2001 May-Jun |
|
| Effect of L-arginine on the course of experimental colitis. | 2001 Oct |
|
| SREA is involved in regulation of siderophore biosynthesis, utilization and uptake in Aspergillus nidulans. | 2001 Sep |
|
| Clinical and molecular findings in hyperornithinemia-hyperammonemia-homocitrullinuria syndrome. | 2001 Sep 11 |
|
| Interstrand side chain--side chain interactions in a designed beta-hairpin: significance of both lateral and diagonal pairings. | 2001 Sep 12 |
|
| Allosteric control of the oligomerization of carbamoyl phosphate synthetase from Escherichia coli. | 2001 Sep 18 |
Patents
Sample Use Guides
Measurement of Ca2+-dependent chloride currents in Xenopus laevis oocytes facilitated the deorphanization of human family C G-protein-coupled receptor hGPRC6A/homologous goldfish 5.24 receptor chimeric construct (h6A/5.24) and identification of L-amino acids as agonists. The most active agonists were L-Arg, L-Lys, and L-ornithine, suggesting that these may function as endogenous signaling molecules (only L-Arg, L-Lys, and L-ornithine were able to activate h6A/5.24 at 10 uM concentration).
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
HBK84K66XH
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
1311542
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | RxNorm | ||
|
221-678-6
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
2097
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
DTXSID50858851
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
SUB32326
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
100000085483
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
118360
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
SUB03542MIG
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
20724-48-5
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
NON-SPECIFIC STOICHIOMETRY | |||
|
DBSALT002530
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
3184-13-2
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
76654
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY | |||
|
HBK84K66XH
Created by
admin on Mon Mar 31 19:16:45 GMT 2025 , Edited by admin on Mon Mar 31 19:16:45 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
